Over two decades of dedication in the field of original innovative drug development have earned us high recognition and encouragement from both within and outside the industry.
Chipscreen Biosciences was listed among the "Best ESG STAR Market Listed Companies". Chidamide was awarded the "China Pharmaceutical Innovation Pioneer Award" by the CBA-China Conference Organizing Committee in collaboration with Pharmacodia.
Chengdu Chipscreen Pharmaceutical was recognized as a “Chengdu Enterprise Technology Center” by the Chengdu Municipal Bureau of Economy and Information Technology.
Chipscreen Biosciences was rated as a national-level “Little Giant” enterprise by the Ministry of Industry and Information Technology.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the Fifth “Jinsha Friendship Award” by the Chengdu Municipal People's Government.
Chipscreen Biosciences received the “2023 Forbes China ESG Innovative Enterprise” award from Forbes China.
Chipscreen Biosciences was rated A in the first information disclosure rating of STAR Market listed companies by the Shanghai Stock Exchange.
Chengdu Chipscreen Pharmaceutical was recognized as a "Sichuan Provincial Specialized, Refined, Unique, and New SME" by the Sichuan Provincial Department of Economy and Information Technology.
The project "Development and Application of Chidamide, a Novel Epigenetic Modulator and Original Anti-Tumor Innovative Drug" was awarded first prize in the 2022 Shenzhen Technological Invention Award by the Shenzhen Municipal People's Government.
Chengdu Chipscreen Pharmaceutical was certified as a national high-tech enterprise for the first time.
Chiglitazar Sodium was awarded the "Annual New Drug Innovation Award (Domestic)" by People's Daily Health Client and People's Daily Health Times.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, received the 2021 CABS K. Fong Award in Life Sciences from the Chinese American Biopharmaceutical Society (CABS).
Chidamide, as a major scientific and technological achievement in the pharmaceutical field, was selected for the "Centennial Review: The Communist Party of China Leading the Development of Science and Technology" exhibition during the 2021 National Science and Technology Week, hosted by the Ministry of Science and Technology of China, in tribute to the centenary of the Communist Party of China.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was awarded the title of "Outstanding Inventor of the Year" in the Sixth Guangdong Outstanding Inventor Awards.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences was recognized as an "Outstanding Innovative Talent" and honored among the Innovation and Entrepreneurship Figures and Advanced Model Figures in commemoration of the 40th anniversary of the establishment of the Shenzhen Special Economic Zone.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, received the "Mayor's Award" in the 2018 Shenzhen Science and Technology Awards.
Chipscreen Biosciences was awarded the title of "Outstanding Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of the People's Republic of China".
Chipscreen Biosciences was honored as a "Leading Enterprise" among the Top 20 Leading Biotech Companies in Shenzhen 2019.
Chipscreen Biosciences' original achievements were invited to participate in the exhibition celebrating the 40th anniversary of reform and opening-up at the Shenzhen Museum, with physical artifacts related to the anti-tumor innovative drug “Chidamide” being collected by this museum.
Chidamide was selected for the "Great Change – Celebrating the 40th Anniversary of Reform and Opening-Up Large-Scale Exhibition".
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, was honored as a "Trailblazer in the Pharmaceutical Industry" commemorating 40 years of reform and opening-up.
Chipscreen Biosciences' "Chemical Innovative Drug Engineering Technology Research Center" was recognized as a provincial-level engineering technology research center.
Dr. Lu Xianping, Chairman of Chipscreen Biosciences, received the "2017 China Pharmaceutical Development Award for Outstanding Achievement in Innovative Drug Development".
Chidamide was awarded the "19th China Patent Gold Award".
Dr. Lu Xianping, President of Chipscreen Biosciences, was elected as the "Scientific Chinese 2016 Person of the Year".
Chidamide was honored as the "Most Clinically Valuable Innovative Drug" among the 2016 China Pharmaceutical Innovation Brands.
Chipscreen Biosciences was recognized as a "National High-Tech Enterprise" and a "Shenzhen High-Tech Enterprise".
Dr. Lu Xianping, President of Chipscreen Biosciences, was named the "Most Influential Innovator in China's Pharmaceutical Innovation 2015".
Dr. Lu Xianping, President of Chipscreen Biosciences, received the inaugural Pacific Life Science Achievement Award at the 11th Annual Conference of the Sino-American Biotechnology and Pharmaceutical Association (SABPA).
Dr. Lu Xianping, President of Chipscreen Biosciences, was selected as one of Forbes' 2015 China-U.S. Innovators.
Chipscreen Biosciences was awarded the "Award for R&D Achievement of the Year 2014" by BayHelix and BioCentury.
Chipscreen Biosciences received the "First Prize of the National Science and Technology Progress Award".
Chidamide was honored with the Excellent Product Award at the 15th China International High-Tech Achievements Fair.
The targeted anti-tumor innovative drug—the novel epigenetic inhibitor "Chidamide"—was selected for the National 863 Program Major Achievements Touring Exhibition.
"Research and Development of the Innovative Anti-Tumor Drug—Chidamide" was included in the "Eleventh Five-Year Plan" National Major Scientific and Technological Achievements Exhibition.
On the occasion of Shenzhen's 30th anniversary, General Secretary Hu Jintao inspected the "Shenzhen Strategic Emerging Industries Exhibition". Chipscreen Biosciences, as a leading enterprise in China's innovative drug sector, was one of the 16 outstanding enterprises participating in the exhibition.
Chipscreen Biosciences was awarded the "Special Contribution Award" by the Center for Drug Evaluation of the China Food and Drug Administration.
Chipscreen Biosciences was recognized as a Shenzhen Intellectual Property Advantage Enterprise.
Chipscreen Biosciences was honored as the "Most Valuable Partner" by Roche R&D Center (China).
Chipscreen Biosciences was awarded the title of "Deloitte Technology Fast 50 China 2008".
Chipscreen Biosciences was recognized as a "Shenzhen Leading Enterprise in Independent Innovation Industry".
Chipscreen Biosciences received the "Shenzhen Science and Technology Innovation Award 2007".
Chipscreen Biosciences' "Chemical Innovative Drug Engineering Technology Center" was accredited as a municipal-level engineering center.
Chipscreen Biosciences was selected for the "2002 Shenzhen Top Ten High-Tech Start-ups—Most Technologically Innovative Enterprise" award.
Chipscreen Biosciences was chosen as one of Asia's "Top 10 Companies to Watch" at the Asia-Pacific Life Sciences and Technology Summit.
